Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


17th International Conference on Nephrology & Urology

London, UK

Nouman Khan

Nouman Khan

Shaukat Khanum Cancer Hospital Lahore & Research Centre, Pakistan

Title: Ten-year outcome study in a cohort of non-metastatic renal cell carcinoma treated with curative intent at SKCH & RC: survival and progression after radical nephrectomy in 344 patients


Biography: Nouman Khan


Background: Radical nephrectomy (RN) is a standard treatment of cure for non-metastatic renal cell carcinoma (NMRCC).
Long-term outcome data are limited for Pakistani population. Our aim was to assess the long-term outcomes of RCC (renal
cell carcinoma) treated with curative intent with radical nephrectomy (RN).
Objectives: To study the 5 and 10 years of outcomes in patients with NMRCC who underwent radical nephrectomy.
Methods: This is a retrospective analysis of prospectively collected data between February 2006 and December 2016. We
included all the adult patients (age ≥ 18 years) with NMRCC from both genders irrespective of their histologic subtypes who
underwent radical nephrectomy (RN) with a curative intent. The data were analyzed for overall survival and recurrence rates
at 5 and 10 years using Kaplan-Meier survival analysis. Multivariate analysis was done using Cox-regression to identify risk
factors associated with poor overall outcome in terms of recurrence and mortality.
Results: 344 patients with 195 (55.5%) males and 149 (44.2%) females with a mean age of 53.5±14.1 years were followed for a
mean follow-up of 31.1±26.77 months (range: 3–132 months), with 46 (13.4%) deaths. 49 (14.2%) cases had disease recurrence
with 33 (9.5%) deaths from disease progression. The five-year progression-free survival was 37% (95% CI: 49.04– 2.76) with
the median time to recurrence was 33 months (95% CI: 27.6–38.4) and the median overall survival was 103.7 months (95%
CI: 95.7–111.7). The five-year overall survival was 76.1% (95% CI: 75.2–77) while 10-year survival was 70.8%. There was a
significant median survival difference for cases with and without recurrence (log-rank χ2: 117.5, p<0.001) T stage, Fuhrman’s
grade, and early postoperative recurrence.
Conclusion: Radical nephrectomy offers the best survival for non-metastatic renal cell carcinoma patients with excellent
postoperative survival and progression-free profile.